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Background: Severe atopic dermatitis (AD) is a recurrent and debilitating disease often
requiring systemic immunosuppressive treatment. The efficacy of cyclosporine A (CsA) is
well proven but potential side effects are concerning. Several reports point at extracor-
poreal photopheresis (ECP) as an alternative treatment modality with few and mild side
effects. However, no direct comparison between CsA and ECP in the treatment of AD has
been performed so far.
Objectives: To compare the efficacy of CsA (3 mg/kg/day) and ECP (administered two
consecutive days twice a month) in a cohort of patients with severe AD.
Methods: A randomized cross-over study involving twenty patients with severe AD (SCO-
RAD index 41-89) refractory to other treatments.The patients were allocated to a 4-month
course of either of the two treatment modalities. Individual relapse periods (2–8 weeks)
were interspersed before cross-over to the other treatment modality. Treatment efficacy
was evaluated by SCORAD, PRURITUS (VAS-index 0–10), “overall global assessment” and
serological biomarkers; sIL-2Rα, sE-selectin, eosinophilocytes, basophilocytes, and sIgE.
Results: 15 patients completed treatment. Both treatments lead to a marked and signifi-
cant decrease in SCORAD and pruritus index. The average reduction of the SCORAD and
pruritus index, respectively was a little higher for ECP treatment compared to CsA treat-
ment; however, the differences did not reach statistical significance. The “overall global
assessment” was significantly better in patients who underwent ECP therapy as com-
pared to CsA treatment. None of the biomarkers showed significant changes after either
treatment when compared to the initial values.
Conclusion: ECP administered on two consecutive days twice a month to patients with
severe AD has similar potency as CsA administered daily in a moderate dose. ECP is a
treatment alternative in patients with severe AD that do not tolerate or are refractory to
conventional immunosuppressants.
Keywords: atopic dermatitis, cyclosporine, extracorporal photophoresis, comparative study, crossover study,
biomarkers
INTRODUCTION
Severe atopic dermatitis (AD) is a recurrent and debilitat-
ing disease often requiring systemic immunosuppressive treat-
ment. Several immunosuppressants, including azathioprine and
methotrexate, are known to exert acceptable disease control in
many cases of AD. The most efficient and fast acting immunosup-
pressant for AD is well recognized to be cyclosporine A (CsA),
which therefore often constitutes first-line immunosuppressive
therapy in severe and recalcitrant cases of AD. Unfortunately,
the potential side effects are concerning in relation to long-
term use and efficient alternatives to CsA in AD are warranted
(1–5). Extracorporeal photopheresis (ECP) is a procedure that
combines leukopheresis with the administration of either oral
8-methoxypsoralen (8-MOP) prior to leukopheresis or the injec-
tion of liquid methoxypsoralen into a leukocyte-rich cell extract.
In practice, the patient’s blood is removed and undergoes cen-
trifugation in order to separate it into a fraction that is depleted
of leukocytes, which is immediately returned to the patient, and a
leukocyte-rich fraction. The leukocyte-rich or buffy coat fraction is
then exposed to UVA light within the ECP unit and re-infused back
into the patient. The entire procedure takes approximately 3 h to
complete (6–8). ECP was originally introduced in the treatment of
cutaneous T-cell lymphoma (CTCL) in the early 1980s. Since then,
several indications for ECP have been proposed in medicine and
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dermatology including bullous pemphigoid (BP), connective tis-
sue disorders, CTCL, epidermolysis bullosa acquisita (EBA), graft
versus host disease (GVHD), lichen planus (chronic erosive type),
multiple sclerosis (MS), pemphigus foliaceus, pemphigus vulgaris,
post-transplant B-cell lymphoma, psoriasis, rejection of renal, car-
diac, and lung transplants, rheumatoid arthritis, and systemic scle-
roderma (7). The use of ECP on a larger scale has, however, been
limited to the treatment of GVDH, CTCL stage III-IV, and scle-
roderma (7, 9–11). In GVHD efficacy has proven comparable to
combined immunosuppressant treatment with CsA and Azathio-
prine (12, 13). It has been suggested that the immunomodulating
effect of ECP may be ascribed to restoration of Th1/Th2 imbal-
ance thus making ECP an obvious treatment option for AD (11).
The first case reports on treatment of AD with ECP was published
in 1994 (14); since then several small open-labeled studies have
consistently reported promising results of ECP in patients with
moderate to severe AD recalcitrant to other treatments. Moreover,
in these reports the side-effects appear rare and mild (6, 8, 15–18).
However, controlled trials comparing ECP and CsA in AD have
never been reported. In here, we report a randomized cross-over
study comparing ECP and CsA as treatment modalities in mod-
erate to severe AD. Evaluation was based on SCORAD, patient
ranking of “global assessment” and pruritus. Moreover, several
biomarkers earlier reported to reflect AD activity were evaluated
during the trial.
MATERIALS AND METHODS
Twenty patients (age 20–45 years, 15 male, 5 female) with chronic
(8–45 years) severe AD (SCORAD 40–89) were included in a
cross-over trial evaluating Cyclosporine A (CsA), 3 mg/kg admin-
istered daily (Sandimmun Neoral®, Novartis Denmark) versus
ECP (2 J/cm2 (Therakos UVAR®, Berkshire, UK) administered on
two consecutive days with intervals of 14 days. The patients were
initially treated with oral 8-MOP, 0.6 mg/kg, followed by photo-
pheresis 2 h later. This regime, however, resulted in inconsistent
blood levels of psoralen. Furthermore, intolerable side-effects to
the oral 8-MOP were noted in our group of patients. For these
reasons, clinical policy on this area was revised, and administra-
tion of 8-MOP was changed to extracorporeal administration of
methoxsalen (Uvadex®, Therakos, Berkshire, UK) in all patients.
When treated with cyclosporine, the patients underwent the fol-
lowing laboratory tests prior to start up and every second week
during the treatment period: complete blood count, assays of
electrolytes, serum creatinine (taken twice before initiation of the
therapy), blood urea nitrogen, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, γ-glutamyltransferase,
lactate dehydrogenase, and bilirubin. Also the blood pressure was
measured before and every second week during treatment.
Duration of treatments was 4 months each with an individual
relapse period (of 2–8 weeks) interspersed. Criteria of inclusion
were refractoriness to standard topical treatment (corticosteroid
ointments, UVA, UVB, PUVA, tar). Criteria of exclusion were preg-
nancy, uncontrolled hypertension, previous malignancy, infec-
tious disease, liver/kidney disease, or active treatment with ECP or
immunosuppressants within 4 weeks prior to start of trial. Patients
were randomized to either treatment after giving their written
informed consent. The use of topical emollients was allowed
during the course of the trial. Corticosteroid creams and ointments
were allowed until 2 weeks prior to trial. During treatment, SCO-
RAD index (19, 20) was recorded monthly. Furthermore, patients
were asked to report pruritus index (on a VAS scale 0–10) during
each clinical visit. At the end of each treatment course, the patients
evaluated the effect on an “overall global assessment” scale (0–5)
reporting their experienced grade of improvement. The following
serological biomarkers were determined at the beginning and at
the end of each treatment course: sIL-2Rα (pgms/mL), sE-selectin
(ngms/mL), eosinophilocytes (billions/mL), basophilocytes (bil-
lions/mL), and sIgE (IE/mL). sIL-2Rα and sE-selectin were deter-
mined by means of ELISA (Abcam®, Cambridge, UK). The rest of
the biomarkers were determined by standard analysis.
The reduction in SCORAD and pruritus index over the two
treatment periods was compared between treatment modalities
with correction for potential crossover effects using a linear mixed
model with systematic effect of treatment sequence, treatment, and
period (/carryover) and a random subject effect (PROC MIXED,
SAS/STAT® software, SAS Institute Inc. SAS OnlineDoc® 9.1.3.
Cary, NC: SAS Institute Inc, 2004).The parameters analyzed by
this test are given in Table 1.
The overall global assessment score and the results from the
analysis of biomarkers were analyzed under the assumption of no
crossover effects and compared between treatment modalities by,
respectively, the Wilcoxon rank sum test with continuity correction
and the paired t -test.
The trial was approved by the Danish National Committee on
Health Research Ethics.
RESULTS
SCORAD AND PRURITUS
The trial set-up is depicted in Figure 1. Of the 20 patients included
for the trial, 15 patients completed both courses of treatment.
One patient dropped out during terminal ECP treatment (due
to pregnancy) and fours patients chose to leave the study during
the terminal course of CsA. A number of non-severe side effects
were stated as contributing factors to the decision to discontinue
the treatment. However, a high degree of satisfaction with the
prior ECP treatment, which often were experienced completely
free of side effects, may also have added to the patients decision.
All four patients who dropped out of CsA had a marked response
Table 1 |The reduction in SCORAD and pruritus index over the two
treatment periods was compared between treatment modalities with
correction for potential crossover effects using a linear mixed model
with systematic effect of treatment sequence, treatment and period
(/carryover) and a random subject effect.
Period 1 Period 2
Sequence CsA-ECP Reference +ECPxtra+ carryover
Sequence ECP-CsA +ECPxtra+ sequence +sequence+ carryover
The systematic effects were parameterized with reference in sequence group CE
and first period (in which the treatment modality was CsA). Based on this refer-
ence three add-on effects (ECPxtra, sequence, carryover/period) can be estimated
as illustrated in the table.
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ECP
CsA
ECP
CsA
4 month therapy4 month therapy
Cross-over  
4-8 weeks
wash-out
Drop-out:n=0
Drop-out:n=0
n=10
n=10
Drop-out:n=1
Drop-out:n=4
9 patients completed:
CsA X ECP
6 patients completed 
ECP X CsA
20 patients
Mean 32.8 y.o.
5 women
15 men 
n = 10
n = 10
Randomization  
FIGURE 1 | Outline of the clinical trial set up. For details please see the Sections “Materials and Methods” and “Results” of the text.
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FIGURE 2 | Normalized SCORAD index (A) and normalized pruritus
index (B) versus duration of treatment with either CsA or ECP. Data
from all patients completing at least 2 months of treatment with CsA
(3 mg/kg/day) (n= 16) or ECP (2 J/cm2, on two consecutive days/14 days)
(n=20) are included.
to the prior ECP treatment (data not shown). As indicated in
Figure 1, individual relapse periods of 2–8 weeks were allowed
before cross-over. Relapse periods for CsA were in general found
to be approximately 1–2 weeks shorter than seen for ECP (results
not shown). In Figure 2, all obtained data for SCORAD (a) and
pruritus (b) are shown. As can be seen, there was a clear and com-
parable tendency toward reduction of SCORAD and pruritus for
both treatments. When similar plots were done for the separate
parameters constituting the SCORAD score, similar decreasing
tendencies were seen for all parameters (results not shown). Thus,
a general and comparable reduction of the symptoms associated
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FIGURE 3 | SCORAD score (A) and pruritus index (B) before and after
4months of treatment with either CsA, 3mg/kg/day or ECP, 2 J/cm2,
on two consecutive days every second week. For details please confer
the Section “Results” of the text.
with severe AD was seen for both treatments. In Figure 3, the
average SCORAD (a) and pruritus index (b) before and after each
of the two treatments is shown for the 15 patients who completed
both treatments. The actual numbers are given in Table 2. Substan-
tial variation in disease severity is reflected in high variance within
groups. However, a clear reduction is seen for both treatments.
When considering the 15 patients who underwent both treatments,
we found in ECP treated patients, one patient with a reduction of
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Table 2 | Patient “overall global assessment” before and after
4months of treatment with either CsA, 3mg/kg/day or ECP, 2 J/cm2,
on two consecutive days every second week.
Score 0 1 2 3 4 5 Mean±SD
ECP (n=19) 0 1 2 5 9 5 3.5±1.0
CsA (n=16) 1 3 5 6 1 0 2.2±1.0
Score: 0=progression; 1= status quo; 2= slight improvement; 3=moderate
improvement, 4= strong improvement, 5= very strong improvement. For each
treatment is given the number of patients having reported each of the possible
scores. Moreover, the average score for each treatment are given in the table.
50 SCORAD points, six patients with a reduction in SCORAD of
30–40 points, and four who showed a reduction of 20–30 points.
The remainder four patients had no crucial improvement. Thus,
73% of the patients responded to ECP therapy. For CsA in this
group, SCORAD diminished by 30–40 points in two patients,
three patients experienced a reduction of 20–30 points, four had
a reduction of SCORAD of 10–20 points, and six had no sub-
stantial reduction or even worsening of their disease. Thus, 60%
responded to the CsA treatment. The reduction of SCORAD seen
with ECP was marginally higher than found for CsA treatment.
Among ECP treated patients, two experienced a 50 points reduc-
tion of their pruritus, one patient had a reduction of pruritus by
30–40 points, five patients experienced reductions of 20–30 points,
two patients reported reductions of 10–20 points while itching was
aggravated in five patients during the course of treatment. Thus,
67% responded positively to ECP. Among the CsA treated individ-
uals, pruritus was reduced by 30–40 points in one patient, three
patients had reductions of 20–30 points, five patients experienced
a reduction of 10–20 points while the remainder experienced very
modest improvement or even aggravation of pruritus. Thus, the
positive response rate for CsA treatment was 60%. The reduction
of both SCORAD and pruritus index during CsA treatment was
significant (p= 0.0098 and 0.0013, respectively). An additional
reduction in both SCORAD and pruritus was estimated with the
ECP treatment [SCORAD: 6.29, CI95% (−7.68; 20.2); pruritus:
0.58, CI95% (−1.40; 2.56)] although statistically non-signficant in
both cases (SCORAD: p= 0.3632; pruritus: p= 0.5503). None of
the estimated add-on effects reached statistical significance (results
not shown). Assuming no carry-over or sequence effects, the data
could be analyzed by the paired t -test. Also this test revealed no
statistical difference between the data obtained with ECP and CsA,
respectively: p= 0.4 for ∆SCORAD and p= 0.5 for ∆pruritus.
OVERALL GLOBAL ASSESSMENT
In Table 2, patients “overall global assessment” scores are sum-
marized for all patients completing a full course of treatment of
either of the two treatments. ECP was rated “good” or “very good”
by 74% of participants while only 6% gave this rating to the CsA
treatment. Mean score for ECP was 3.5 compared to 2.2 for CsA.
This difference was statistically significant (p= 0.0012).
BIOMARKERS
Certain biomarkers associated to AD have been claimed to be
altered in response to treatment with ECP and/or CsA in AD
patients. These include decrease of serum concentration of IgE
and eosinophilic granulocytes in patients treated with either ECP
or CsA (14, 21–23). Moreover, the serum level of sIL-2R and
sE-selectin has been reported to be decreased in AD patients
responding to ECP treatment (21). In an attempt to correlate
these biomarkers to the efficacy of the two treatments modalities,
the biomarkers were determined in each patient before and after
each completed treatment modality. Basic measurement deviation
and baseline values in healthy individuals were not assessed. How-
ever, the determinations of basophilic granulocytes were included
as an internal marker, which is not expected to reflect AD activ-
ity. A number of samples failed thus leaving us with valid data
from 10 to 12 patients in each set of data (see Table 3). As can be
seen from the table, no drastic changes of any of the biomark-
ers were found in response to either of the treatments. When
analyzed by paired t -test no significant differences between the
results obtained with ECP and CsA was found: basophilic granu-
locytes: 1.21, CI95%: (0.74, 1.97), p= 0.4126; eosinophilic granulo-
cytes: 1.10, CI95%: (0.63; 1.91), p= 0.7226; E-selectin: 0.90, CI95%:
(0.66; 1.24), p= 0.4689; sIgE: 0.99, CI95%: (0.64; 1.53), p= 0.9394;
sIL-2Ralpha: 1.64, CI95%: (0.65; 4.16), p= 0.2628.
ADVERSE EFFECTS
Extracorporeal photopheresis was well tolerated by all patients
without clinically obvious adverse effects. In contrast to this, a
number of adverse reactions were reported for CsA. These are
summarized in Table 4. All the listed symptoms are known to be
potential adverse effects to treatment with CsA. Most symptoms
were relatively mild and none of the patients who redrew from the
CsA treatment pointed at adverse reactions as the only reason for
their drop out. No persistent increments of more than 25% were
seen for any of the initial values of the laboratory test in any of the
patients. Thus, we found no sign of impaired kidney function as a
result of the CsA treatment.
DISCUSSION
Treatment with CsA is established as highly efficient for moder-
ate to severe AD. Earlier reports have pointed at ECP as a valid
alternative. In this study, we have compared standardized courses
of ECP and CsA, respectively. The obtained results allow us to
conclude that both treatments are efficacious for severe AD. More-
over, the results show that under the given conditions, ECP was
equipotent to the applied CsA regime in reducing disease activ-
ity as measured by SCORAD and pruritus index, respectively. In
fact, a tendency of ECP being marginally more potent than CsA
may be traced from the data. However, certain circumstances may
have contributed to a seemingly lesser effect of CsA compared to
ECP. Serum cyclosporine values or metabolism was not exam-
ined. Such an analysis would have helped assessing effect and
compliance with respect to the CsA treatment. Also, CsA dose
needed to treat AD may vary depending on patient susceptibility
as well as the period of time of the treatment. Former clinical tri-
als have thus used CsA in higher doses (1, 4, 24–26). In this trial,
we used the recommended starting dose. ECP was administered
with an optimized frequency and dosing (15). Moreover, although
not significant in our statistical analysis, minor carry-over effects
cannot be excluded. Thus, a positive carry-over effect from the
Frontiers in Medicine | Dermatology October 2014 | Volume 1 | Article 33 | 4
Koppelhus et al. Photophoresis versus cyclosporine in severe atopic dermatitis
Table 3 | Average values for SCORAD, pruritus index, sIgE, sIL-2Rα, sE-selectin, eosinophilocytes, and basophilocytes before and after 4months
of treatment before with either CsA, 3mg/kg/day or ECP, 2 J/cm2, on two consecutive days every second week.
ECP CsA
Before After ∆ (%) Before After ∆ (%)
SCORAD 69±16
(n=15; range: 50–82)
37±16
(n=15; range: 11–66)
−46 67±11
(n=15; range: 41–82)
44±16
(n=15; range: 22–83)
−34
Pruritus 6.5±1.8
(n=15; range: 5–10)
2.4±1.8
(n=15; range: 0–6)
−63 7.3±2.1
(n=15; range: 3–10)
4.0±2.5
(n=15; range: 1–9)
−45
S-Il-2Rα 1650±298
(n=12; range: 1209–4383)
1720±986
(n=12; range: 1031–2984)
4 1756±913
(n=12; range: 1013–4516)
1473±1029
(n=12; range: 835–4383)
−16
S-E-selectin 74±23
(n=10; range: 25–101)
77±35
(n=10; range: 27–132)
4 77±35
(n=10; range: 29–130)
76±32
(n=10; range: 26–122)
−1
IgE 6341±6509
(n=11; range; 103–17133)
5936±6534
(n=11; range; 78–16.783)
−6 5742±7605
(n=10; 353–24.459)
5224±5152
(n=10: 155–14.166)
−9
Basophilic
granulocytes
0.054±0.016
(n=12; range: 0.03–0.09)
0.056±0.014
(n=12; range: 0.05–0.09)
4 0.06±0.015
(n=11; range: 0.03–0.08)
0.046±0.022
(n=11; range: 0.00–0.08)
−23
Eosinophilic
granulocytes
0.69±0.39
(n=12; range: 0.03–1.56)
0.63±0.50
(n=12; range: 0.14–1.9)
−9 0.85±0.54
(n=12; range: 0.27–1.77)
0.54±0.36
(n=12; range: 0.14–1.14)
−36
For further details please confer the text in the Section “Results.”
Table 4 | Adverse effects to treatment with CsA registered during the
trial.
Adverse effect reported n
Headaches 4
Gingival hypertrophy and/or bleeding 2
Tremor 2
Gastrointestinal symptoms 2
Flushing 2
Hypertension 1
Hypertrichosis 1
Metallic taste 2
Infections 1
CsA treatment modality to the ECP treatment modality in the
CsA-ECP sequence group could not be excluded.
The drop out of CsA treatment amounted to 40% among the
patients who had completed ECP therapy as their first course of
treatment. This was probably in part due to greater satisfaction
with the prior ECP treatment. The high satisfaction with ECP was
also reflected in significantly better “patient overall global assess-
ment” score for this treatment. Compliance to ECP therapy was
remarkably high. Adherence to this treatment may have been ame-
liorated by the fact that treatment is “tablet-free.” Moreover, the
high compliance to ECP treatment being the more time consum-
ing may also have been improved by the fact that many patients
were out of job due to their extensive AD disease.
The pathogenesis of AD is complex and involves geneti-
cally determined epidermal barrier dysfunction and characteristic
immunological deviations. The latter include elevated serum IgE
levels, eosinophilia, and T-helper type 2 (Th2)-skewed cytokine
patterns in the acute phase of the disease and increased num-
bers of circulating regulatory T cells. sIL-2Rα and sE-selectin have
been claimed to correlate to disease severity (SCORAD) and to
efficacy of treatment with CsA and ECP in previous studies (21,
27). Also, a decrease in IgE and eosinophilic granulocytes have
been claimed in response to these treatments (22, 23, 28–30). Our
results did not confirm these findings. In fact, only small and
insignificant changes were found for all the tested biovariables.
The more prominent (but statistically insignificant) decrease in
serum concentration of eosinophilic and basophilic granulocytes
in CsA treated patients may simply represent a more or less gen-
eralized inhibitory effect of CsA on lymphocyte proliferation and
not a cellular reflection of disease activity at a given time. However,
taken together our results lacked statistical strength and more data
correlating serological markers, disease activity of AD, and per-
haps histology in patients treated with ECP and CsA, respectively
are warranted.
In summary, we found a standard treatment with ECP to exhibit
similar potency to CsA therapy given in a dose of 3 mg/kg/day for
moderate to severe AD. The profile of safety for long-term treat-
ment with ECP is only reported in few small studies (6) but side
effects are seemingly rare and mild and B- and T-cell immunity is
left unaltered (18, 31). Nevertheless, due to the cost being five times
higher for ECP treatment than treatment with CsA, immunosup-
pressants will probably remain the mainstay in patients needing
lengthy treatment of AD. However, ECP may serve as a valu-
able alternative to systemic treatments with immunosuppressants
when such treatment is not tolerated (e.g., due to side effects) or
acceptable for the patient.
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